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reactivity during chronic DAPT with clopidogrel 
and acetylsalicylic acid among obese and normal- 
-weight individuals are the main findings of the ar-
ticle by Haberka et al,9 published in the current is-
sue of the Polish Archives of Internal Medicine. One of 
strong points of the study was a homogenous study 
group, which consisted solely of patients with sta-
ble CAD after elective PCI with stent implantation. 
Moreover, unlike most of other studies, Haberka 
et al9  assessed platelet function not only early af-
ter the administration of a loading dose of clopi-
dogrel, but also 1 month after PCI during DAPT. 
It may shed additional light on the problem, since 
the majority of previous studies have assessed only 
early platelet reactivity and extrapolated the re-
sults to an overall on-treatment platelet response.
The authors claimed that the association be-
tween obesity and platelet reactivity was com-
plex and biphasic. Noteworthy, platelet response 
to clopidogrel deteriorated in all 3 groups: lean, 
overweight, and obese. In obese patients, plate-
let reactivity when stimulated with ADP (which 
is a measure of their response to clopidogrel) was 
higher after the loading dose of clopidogrel and 
increased slightly 1 month after PCI. Of note, in 
the lean group, it increased twice over 1 month. 
However, it is unclear whether those changes in 
time were significant. Nonetheless, similar plate-
let reactivity after 1 month of a maintenance dose 
of clopidogrel in obese, overweight, and lean pa-
tients was mainly the result of deterioration in 
platelet response to clopidogrel in lean patients. 
Interestingly, the change in platelet reactivity was 
inversely associated with body mass index and 
waist circumference. In other words, the thinner 
the person was, the higher the increase in plate-
let reactivity developed over time. According to 
Haberka et al,9 one may observe the “leanness 
paradox” in a deteriorating platelet response to 
clopidogrel. A multivariate analysis showed that 
besides BMI, also creatinine, male sex, and active 
smoking were the independent predictors of the 
worsening of platelet response to clopidogrel.
Obesity is a growing health problem associat-
ed with numerous other pathologies, primarily 
with cardiovascular (CV) diseases and diabetes. 
Moreover, adipose tissue is at present considered 
to be an important endocrine organ, which pro-
duces adipose-derived hormones—adipokines.1,2 
The so called “obesity paradox” described in pa-
tients with cardiovascular diseases3 confirms a 
complex role of adipose tissue and its properties 
to modulate numerous physiological and patho-
logical processes.
Dual antiplatelet therapy (DAPT) is a gold stan-
dard of treatment after percutaneous coronary 
intervention (PCI) with stent implantation, and 
its efficacy is indispensable for the success of the 
procedure and improvement in patient survival. 
Despite a well-grounded position of antiplate-
let drugs in CV pharmacotherapy, low response 
to those drugs is relatively common.4 There have 
been attempts to overcome the resistance of plate-
lets to clopidogrel, for example, by increasing its 
dose5 or adding omega-3 polyunsaturated fatty ac-
ids.6 Moreover, there are new promising antiplate-
let drugs administered in patients with acute cor-
onary disease, such as prasugrel, ticagrelor, and 
cangrelor. They have been shown to be more po-
tent antiplatelet strategies, simultaneously rais-
ing concerns on a possible increase of bleeding 
risk compared with clopidogrel. Further studies 
with new antiplatelet drugs are required to assess 
their efficacy and safety in patients with stable 
coronary artery disease (CAD), especially in those 
with low platelet response to clopidogrel. Consid-
ering the extent of the problem and fundamen-
tal role of antiplatelet drugs, it is important to 
identify factors that may affect platelet reactivi-
ty. Obesity is considered one of them.8 However, 
it is possible that high on-treatment platelet re-
activity (HTPR) is not associated with obesity per 
se, but with other risk factors that are found more 
commonly in untreated obese patients.
Impaired platelet response to a loading dose of 
clopidogrel in obese patients, and similar platelet 
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The shortcoming of the study by Haberka et al9 
is a limited study group, especially small number 
of lean patients (26 of 130 patients), which may 
have distorted the results. Moreover, it would be 
interesting to present the subgroup characteris-
tics (eg, sex, smoking, creatinine levels, and the 
presence of various comorbidities) that might 
have affected platelet reactivity. It seems to be 
particularly important because those factors have 
been found to be independent predictors of the 
change in platelet response to clopidogrel in the 
multivariate analysis. Similarly, there is no infor-
mation about differences in inflammatory mark-
ers between the subgroups, even though leuko-
cytes have been associated with platelet reactivity.
In summary, despite the fact that obesity is 
generally perceived as a risk factor of high on-
-treatment platelet reactivity on chronic clopi-
dogrel therapy, the data provided by Haberka et 
al9 suggest the “leanness paradox”, that is, a sur-
prising increase in platelet reactivity in lean pa-
tients 1 month after PCI. It may be particularly 
dangerous because platelet reactivity is usually 
assayed once, just after PCI. Therefore, although 
it is not recommended by the current guidelines, 
monitoring of platelet reactivity on DAPT, espe-
cially in lean patients, may be advisable in order 
to diagnose those with deteriorating clopidogrel 
response. Moreover, it may help identify and ver-
ify the risk factors for HTPR. Finally, further re-
search on a larger population is needed to test the 
hypothesis of the “leanness paradox.”
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It has been shown that low platelet response 
to clopidogrel is more common in patients with 
cytochrome P450 2C19 loss-of-function polymor-
phism, and, interestingly, it increases overtime in 
this group.6 Therefore, it would have been reason-
able to perform genetic testing for that polymor-
phism, since it is a factor that may affect platelet 
function. It is possible that in a relatively small 
population of the study by Haberka et al,9 the pro-
portion of those with cytochrome P450 2C19 loss- 
-of-function polymorphism was higher in the lean 
group, which might have distorted the results. As 
far as we are considered, the article is the first to 
demonstrate an increase in platelet reactivity on 
chronic DAPT in lean patients. It may well be that 
the lean population in the study was a combina-
tion of fit individuals and those with uninten-
tional weight loss due to underlying conditions 
such as frailty or other undiagnosed chronic dis-
eases. The inflammatory reaction related to those 
disorders might have affected platelet function.
The relationship between platelet reactivity and 
inflammation was also assessed by Haberka et al.9 
Authors assayed the easily obtainable and non-
specific markers of the inflammatory state, such 
as white blood count, neutrophil and lymphocyte 
counts, and neutrophil-to-lymphocyte ratio. They 
found that baseline WBC was predictive of platelet 
response to a loading dose of clopidogrel and was 
not associated with platelet reactivity on chronic 
clopidogrel treatment. On the other hand, base-
line lymphocyte count was associated with plate-
let function both at baseline and during follow- 
-up. Nonetheless, inflammatory markers were 
assayed only at baseline, which is a shortcom-
ing of the study. 
PCI-induced injury of the endothelium is a 
strong proinflammatory stimulus. We found that 
systemic inflammatory reaction triggered by PCI 
with stent implantation persists at least 1 month 
after the procedure, and may also account for low-
er platelet response to clopidogrel.10 On the oth-
er hand, systemic low-grade inflammation relat-
ed to fat tissue, which contributes to increased 
platelet turnover in obese individuals, may also 
alter the effect of antiplatelet drugs. Thus, some 
authors suggested a dose adjustment of clopido-
grel in obese patients,11 despite the fact that there 
is no evidence from clinical trials on the bene-
fit of this approach.12 Additionally, it has been 
shown previously that inflammatory response 
triggered by PCI may modulate endocrine activ-
ity of the adipose tissue and result in a decrease 
of adiponectin and increase of leptin concentra-
tions early after the procedure.13 Therefore, it is 
possible that changes of adipokines’ pattern dur-
ing follow-up after PCI may account, at least in 
part, for platelet response to clopidogrel and the 
differences between lean and obese individuals. It 
would be interesting to assess platelet reactivity 
along with fat tissue endocrine function and in-
flammatory indicators in a long-term follow-up 
after PCI with stent implantation in terms of the 
explanation of the “obesity paradox”.
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